Gdańsk, Poland – 21 February 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune diseases, announces today it has appointed Prof. Daniel Shelly, PhD, MBA, into the role of Chief Business Development Officer, to help PolTREG build the strategic, commercial, research and pharmaceutical partnerships that will enable the company to successfully commercialise its strong pipeline of cell therapies for diseases such as Type-1 Diabetes (T1D), Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS).

波兰格但斯克–2024年2月21日–PolTREG S.A.（华沙证券交易所：PTG），一家临床阶段的生物技术公司，开发针对多种自身免疫性疾病的细胞疗法，今天宣布，它已任命MBA博士Daniel Shelly教授担任首席商业开发官，以帮助PolTREG建立战略性、商业性、，研究和药物合作伙伴关系将使该公司成功地将其强大的细胞疗法渠道商业化，用于治疗1型糖尿病（T1D），多发性硬化症（MS）和肌萎缩侧索硬化症（ALS）等疾病。

“I am elated we were able to attract Dan to help us deliver the promise of Treg cell therapies for a wide range of autoimmune diseases. PolTREG has the most comprehensive pipeline of cell therapies for autoimmune diseases, including Type-1 Diabetes and Multiple Sclerosis, and Dan’s arrival will enable us to continue to deliver the milestones that will bring our lead assets closer to market,” said Prof.

“我很高兴我们能够吸引Dan来帮助我们实现Treg细胞疗法治疗多种自身免疫性疾病的承诺。PolTREG拥有最全面的自身免疫性疾病细胞疗法渠道，包括1型糖尿病和多发性硬化症，Dan的到来将使我们能够继续实现里程碑，使我们的领先资产更接近市场。”教授说。

Piotr Trzonkowski, Chief Executive Officer of PolTREG. Dr Shelly is an astute veteran of the life science industry, with a deep understanding of biology and the Treg cell therapies that PolTREG is developing. He has a proven track record of closing business development deals for a wide range of biotech companies, including most recently several early-stage evaluation deals for Prescient Therapeutics Ltd., a clinical stage oncology company developing personalised medicine approaches to cancer, using CAR-T technologies.

He was Director of Global Business Development and Strategic Partnerships for the global non-profit PATH, where he was the Co-Lead for the COVID-19 task force. He is an adjunct associate professor at the University of Cincinnati, where he teaches biologic.

他是全球非营利路径全球业务发展和战略伙伴关系主管，也是新型冠状病毒工作组的联合负责人。他是辛辛那提大学的兼职副教授，教授生物学。

Attachments

附件

20240216 PolTREG PR Dan Shelly - approved

20240216 PolTREG PR Dan Shelly-批准

Daniel Shelly

丹尼尔·雪莉